{"id":"W4205228191","doi":"10.1016/j.annonc.2021.12.012","title":"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Adverse effect; Pharmacokinetics; Carcinoembryonic antigen; Internal medicine; Population; Oncology; Antibody-drug conjugate; Antibody; Cancer; Pharmacology; Gastroenterology; Monoclonal antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004177431,0.000158672,0.0005820193,0.0000998833,0.0001250965,0.000003273053,0.0001584519,0.00003725138,0.00006290239],"category_scores_gemma":[0.0000539393,0.0001271894,0.00004884281,0.0004422454,0.0002508475,0.0000774264,0.0001453869,0.0004111037,3.547872e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006099173,"about_ca_system_score_gemma":0.00009648552,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004985631,"about_ca_topic_score_gemma":0.00002714745,"domain_scores_codex":[0.9984644,0.0001736279,0.0005154319,0.0003123998,0.0002907238,0.0002434277],"domain_scores_gemma":[0.9990457,0.0001380826,0.0003325183,0.0002685984,0.0001388291,0.00007625797],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003007324,0.009263735,0.8527398,0.0001932572,0.0000935795,0.00003757285,0.0005736353,0.001483541,0.1290061,0.00005387297,0.00009732394,0.003450298],"study_design_scores_gemma":[0.01080478,0.002026191,0.9283864,0.0000690894,0.00007209811,0.000009928342,0.0001959252,0.0005104264,0.05697526,0.00003468758,0.0007956603,0.0001195483],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951891,0.00007096995,0.000004201249,0.002957503,0.0000400426,0.001202361,0.00006510983,0.00001067074,0.0004600374],"genre_scores_gemma":[0.9995142,0.000076645,0.00002959434,0.0002283893,0.00002412041,0.00004181463,0.00003715599,0.00001553305,0.00003254144],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07564664,"threshold_uncertainty_score":0.5186633,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02869993499896342,"score_gpt":0.3813805163275267,"score_spread":0.3526805813285633,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}